Boiron SA (FR:BOI)
:BOI
Top Page
Boiron SA
(BOI)
Select Model
Select Model
Rating:69Neutral
Price Target:
€33.00
▲(8.55% Upside)
Action:ReiteratedDate:10/23/25
Boiron SA's overall stock score is driven by strong technical momentum and a stable financial position, despite challenges in revenue growth and profitability. The valuation suggests potential overvaluation, but the dividend yield offers some appeal.
Positive Factors
Balance sheet strength
Very low leverage and a robust equity ratio provide durable financial flexibility. This reduces refinancing risk, supports continued R&D and capex spending, and allows the firm to sustain distributions or absorb shocks without materially increasing financial stress over the medium term.
Negative Factors
Declining revenue trend
A multiyear revenue decline reduces scale and erodes top-line momentum, limiting the company’s ability to leverage fixed costs. Persistent shrinkage can constrain long-term investment in innovation and marketing, weakening competitive position in key markets.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low leverage and a robust equity ratio provide durable financial flexibility. This reduces refinancing risk, supports continued R&D and capex spending, and allows the firm to sustain distributions or absorb shocks without materially increasing financial stress over the medium term.
Read all positive factors
Boiron SA (BOI) vs. iShares MSCI France ETF (EWQ)
Market Cap
€487.02M
Dividend Yield3.95%
Average Volume (3M)4.19K
Price to Earnings (P/E)8.6
Beta (1Y)0.29
Revenue Growth4.80%
EPS Growth-18.25%
CountryFR
Employees2,469
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.21
Shares Outstanding17,545,408
10 Day Avg. Volume1,557
30 Day Avg. Volume4,187
Financial Highlights & Ratios
PEG Ratio-0.60
Price to Book (P/B)1.23
Price to Sales (P/S)0.95
P/FCF Ratio13.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.06
Revenue Forecast (FY)€522.30M
Boiron SA Business Overview & Revenue Model
Company Description
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillo...
How the Company Makes Money
Boiron generates revenue primarily through the sale of its homeopathic products, which are distributed to pharmacies, health food stores, and healthcare practitioners. The company operates in various segments, including over-the-counter (OTC) home...
Boiron SA Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
72
Positive
Cash Flow
68
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 504.86M | 487.56M | 493.25M | 534.24M | 455.20M | 513.58M |
| Gross Profit | 372.12M | 358.76M | 358.08M | 379.73M | 327.62M | 394.74M |
| EBITDA | 56.24M | 45.46M | 73.67M | 91.33M | 78.75M | 68.91M |
| Net Income | 19.37M | 11.34M | 35.83M | 44.67M | 28.56M | 26.21M |
Balance Sheet | ||||||
| Total Assets | 561.59M | 576.33M | 590.20M | 789.49M | 770.70M | 781.82M |
| Cash, Cash Equivalents and Short-Term Investments | 62.45M | 64.71M | 74.04M | 250.94M | 234.50M | 234.69M |
| Total Debt | 18.10M | 14.97M | 13.70M | 22.17M | 12.61M | 12.43M |
| Total Liabilities | 192.47M | 198.15M | 198.70M | 232.15M | 238.93M | 272.65M |
| Stockholders Equity | 369.10M | 378.14M | 393.66M | 557.62M | 531.74M | 509.14M |
Cash Flow | ||||||
| Free Cash Flow | 47.88M | 33.77M | 27.47M | 41.51M | 13.46M | 47.98M |
| Operating Cash Flow | 55.80M | 42.17M | 45.49M | 60.10M | 33.88M | 68.68M |
| Investing Cash Flow | -16.28M | -18.36M | -22.93M | -15.28M | -11.92M | -19.34M |
| Financing Cash Flow | -26.69M | -27.85M | -198.41M | -28.99M | -22.00M | -21.52M |
Boiron SA Technical Analysis
Positive
30.40
Price Trends
27.71
Positive
28.51
Negative
26.37
Positive
Market Momentum
-0.12
Negative
62.84
Neutral
95.39
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BOI, the sentiment is Positive. The current price of 30.4 is above the 20-day moving average (MA) of 26.29, above the 50-day MA of 27.71, and above the 200-day MA of 26.37, indicating a bullish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 62.84 is Neutral, neither overbought nor oversold. The STOCH value of 95.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:BOI.
Boiron SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | €487.02M | 8.56 | 5.18% | 3.95% | 4.80% | -18.25% | |
67 Neutral | €13.56B | 22.37 | 10.82% | 1.17% | 9.57% | -34.30% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
46 Neutral | €443.13M | -5.43 | -58.93% | ― | 13.48% | -1299.09% | |
45 Neutral | €981.81M | -3.62 | -241.12% | ― | ― | 3.09% | |
40 Neutral | €77.57M | -4.03 | ― | ― | -5.08% | -88.04% |
* General Sector Average
FR:BOI
Boiron SA
27.80
5.13
22.65%
FR:DBV
DBV Technologies
3.53
2.25
175.98%
FR:IPN
Ipsen
163.90
65.93
67.29%
FR:ALCOX
Nicox SA
0.41
0.18
80.53%
FR:VLA
Valneva
2.58
-0.41
-13.71%
FR:AB
AB Science SA
1.17
-0.13
-9.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.